Literature DB >> 9363118

Assessment of peak expiratory flow in asthma.

J L Malo1.   

Abstract

Assessment of peak expiratory flow is a test of airway caliber that is simple, inexpensive, and easily performed on an outpatient basis. Because asthma is characterized by fluctuations in airway caliber, such a test can be useful in the diagnosis and assessment of the condition's severity. Although this approach is useful, it has several pitfalls: peak expiratory flow is less sensitive than forced expiratory volume in 1 second in the assessment of airway caliber; compliance with daily assessment on a long-term basis is generally not satisfactory; and daily monitoring of airway caliber may not be more sensitive than symptoms recorded in a diary to identify flare-ups. Peak expiratory flow may be a useful means of asthma assessment for subjects who either under- or over-estimate their symptoms, if the tests are conducted over short intervals of monitoring, and specifically in the investigation of occupational asthma.

Entities:  

Mesh:

Year:  1996        PMID: 9363118

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  3 in total

1.  Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2.

Authors:  D R Baldwin; P Gannon; P Bright; D T Newton; A Robertson; K Venables; B Graneek; R D Barker; A Cartier; J-L Malo; M Wilsher; C F A Pantin; P S Burge
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

2.  Asthma screening of inner city and urban elementary school-aged children.

Authors:  Priyal Amin; Linda Levin; Andrew Smith; Benjamin Davis; Laura Nabors; Jonathan A Bernstein
Journal:  J Asthma       Date:  2013-10-22       Impact factor: 2.515

3.  The validation of work-related self-reported asthma exacerbation.

Authors:  Aimee R Bolen; Paul K Henneberger; Xiaoming Liang; Susan R Sama; Peggy A Preusse; Richard A Rosiello; Donald K Milton
Journal:  Occup Environ Med       Date:  2006-12-20       Impact factor: 4.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.